Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche, OrbiMed And McKinsey's Entrepreneurship Competition Builds Platform For China's Young Biotech Community

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Seeking ways to tap into China's rich talent pool and spark local innovation, Roche, OrbiMed and McKinsey are hoping a SEED business competition can nurture entrepreneurs in China's biotech academic community

You may also be interested in...



Korean Biotechs Battle For Funding and Attention Underneath Chinese Shadow

SEOUL - Korean biotechs are producing siginificant R&D output, but there is a disconnect between local companies' scientific and financial success, and the country needs to utilize new models to build a viable biotech industry, according to panelists at Bio Korea 2010

Korean Biotechs Battle For Funding and Attention Underneath Chinese Shadow

SEOUL - Korean biotechs are producing siginificant R&D output, but there is a disconnect between local companies' scientific and financial success, and the country needs to utilize new models to build a viable biotech industry, according to panelists at Bio Korea 2010

Asia Spotlight: Roche's Joe McCracken On Early-stage Partnering In Asia

On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at 1http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.

Related Content

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel